Anna French

Anna French, D.Phil., joined Qiming US in 2017 from the Boston Consulting Group (BCG), where she was a healthcare management consultant who advised leading pharmaceutical and biotech companies on their strategy and operations, with a focus in cell therapy and regenerative medicine. Previously, she led a global industry-academic consortium centered on cell therapy commercialization, the Centre for the Advancement of Sustainable Medical Innovation (CASMI)’s Translational Stem Cell Consortium, a partnership between Oxford University and University College London.

Anna is a Partner with the fund and currently serves on the boards of Jasper Therapeutics (NASDAQ: JSPR), Umoja Biopharma, and Auron Therapeutics.

Anna earned a D.Phil. from the University of Oxford, UK, where her research focused on the hematological differentiation of human-induced pluripotent stem (iPS) cells. She has authored over 20 publications in the field of stem cell research. Anna received her BSc in Biochemistry with first class honors from the University of Bristol.

Want to work with Anna?

See our latest job openings

See what Anna and their colleagues have been up to:

11/07/2023 Publications Grant Dewson, Pieter J. A. Eichhorn & David Komander

Deubiquitinases in cancer

02/07/2023 News Kelly Bilodeau

Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

Guiding a young, groundbreaking company to maturity calls for a leader who can strike the right balance between oversight and support. Victoria Richon is hoping to provide just that as the new CEO of Entact Bio, a preclinical biotech that came out of stealth in December...

01/06/2023 News Dylan Neel

Entact Bio: Victoria Richon, CEO

The language of drug development is often militaristic. Medicinal chemists build arsenals of small molecules—looking for inhibitors or “warheads” that can hit “targets” and “combat” disease. Block, eliminate, disrupt, halt. For decades, drug makers have sought “magic bullets” that can precisely destroy ...

12/07/2022 News Gina Vitale

Entact Bio launches with $81 million to enhance protein function

When proteins within the body get tagged with a molecule called ubiquitin, they are essentially marked for destruction. But they can be saved; a deubiquitinase enzyme can remove the ubiquitin, keeping the protein intact. That, at least in part, is what Entact Bio aims to do...

See all news & publications